PET/MRI and prostate cancer

Morand Piert, Issam El Naqa, Mathew S. Davenport, Elena Incerti, Paola Mapelli, Maria Picchio

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.

Original languageEnglish
Pages (from-to)473-485
Number of pages13
JournalClinical and Translational Imaging
Volume4
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Positron-Emission Tomography
Prostatic Neoplasms
Diagnostic Imaging
Choline
Patient Care
Magnetic Resonance Imaging
Ligands

Keywords

  • PET/MRI
  • Prostate cancer
  • [C]choline
  • [F]choline
  • [Ga]PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

PET/MRI and prostate cancer. / Piert, Morand; El Naqa, Issam; Davenport, Mathew S.; Incerti, Elena; Mapelli, Paola; Picchio, Maria.

In: Clinical and Translational Imaging, Vol. 4, No. 6, 01.12.2016, p. 473-485.

Research output: Contribution to journalReview article

Piert, M, El Naqa, I, Davenport, MS, Incerti, E, Mapelli, P & Picchio, M 2016, 'PET/MRI and prostate cancer', Clinical and Translational Imaging, vol. 4, no. 6, pp. 473-485. https://doi.org/10.1007/s40336-016-0192-9
Piert, Morand ; El Naqa, Issam ; Davenport, Mathew S. ; Incerti, Elena ; Mapelli, Paola ; Picchio, Maria. / PET/MRI and prostate cancer. In: Clinical and Translational Imaging. 2016 ; Vol. 4, No. 6. pp. 473-485.
@article{20799ab89fde48d4ba8bba7ee0daf657,
title = "PET/MRI and prostate cancer",
abstract = "Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.",
keywords = "PET/MRI, Prostate cancer, [C]choline, [F]choline, [Ga]PSMA",
author = "Morand Piert and {El Naqa}, Issam and Davenport, {Mathew S.} and Elena Incerti and Paola Mapelli and Maria Picchio",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40336-016-0192-9",
language = "English",
volume = "4",
pages = "473--485",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia s.r.l.",
number = "6",

}

TY - JOUR

T1 - PET/MRI and prostate cancer

AU - Piert, Morand

AU - El Naqa, Issam

AU - Davenport, Mathew S.

AU - Incerti, Elena

AU - Mapelli, Paola

AU - Picchio, Maria

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.

AB - Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.

KW - PET/MRI

KW - Prostate cancer

KW - [C]choline

KW - [F]choline

KW - [Ga]PSMA

UR - http://www.scopus.com/inward/record.url?scp=84996587604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996587604&partnerID=8YFLogxK

U2 - 10.1007/s40336-016-0192-9

DO - 10.1007/s40336-016-0192-9

M3 - Review article

AN - SCOPUS:84996587604

VL - 4

SP - 473

EP - 485

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 6

ER -